Literature DB >> 8622334

Role of gamma delta T cells in pathogenesis and diagnosis of Behcet's disease.

A Hasan1, F Fortune, A Wilson, K Warr, T Shinnick, Y Mizushima, R van der Zee, M R Stanford, J Sanderson, T Lehner.   

Abstract

BACKGROUND: Behcet's disease (BD) is a multisystem disorder of unknown pathogenesis. The diagnosis is based on a set of international clinical criteria. Previous investigations have suggested that immunological cross-reactivity between peptides within streptococcal heat-shock proteins and human peptides might be involved in the pathogenesis of BD. We tested four peptides from mycobacterial heat-shock proteins to see if they specifically stimulated gamma delta T cells from BD patients. We then investigated this response to see whether it could be used as a laboratory test to diagnose BD.
METHODS: We used a T-cell proliferative test to assay responses to four mycobacterial 65 kDa heat-shock-protein peptides and to four homologous peptides derived from the sequence of the human 60 kDa heat-shock protein.
FINDINGS: We elicited significant gamma delta T-cell responses to the mycobacterial peptides in 25 (76%) of 33 patients with BD, compared with 2 (3.6%) of 55 controls with recurrent oral ulcers, systemic disease, or no disorders. The proportion of BD patients who had false-negative results decreased if the test was done during clinical manifestation of disease activity. There was a correlation between disease activity and T-cell responses. Four homologous peptides from human 60 kDa heat-shock protein also specifically stimulated T cells from patients with BD but with lower stimulation indices.
INTERPRETATION: Activation of peripheral-blood mononuclear cells with the four heat-shock-protein peptides elicited significant T-cell proliferative responses by the gamma delta subset of T cells, which may regulate alpha beta T cells. Because these peptides have a high specificity for BD, this assay can be used as a laboratory diagnostic test for BD.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8622334     DOI: 10.1016/s0140-6736(96)90868-5

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  40 in total

Review 1.  Pulmonary manifestations of Behçet's disease.

Authors:  F Erkan; A Gül; E Tasali
Journal:  Thorax       Date:  2001-07       Impact factor: 9.139

Review 2.  Imaging of the pulmonary manifestations of systemic disease.

Authors:  A G Rockall; D Rickards; P J Shaw
Journal:  Postgrad Med J       Date:  2001-10       Impact factor: 2.401

Review 3.  Behçet's disease: infectious aetiology, new autoantigens, and HLA-B51.

Authors:  H Direskeneli
Journal:  Ann Rheum Dis       Date:  2001-11       Impact factor: 19.103

Review 4.  Behçet's disease.

Authors:  V Kontogiannis; R J Powell
Journal:  Postgrad Med J       Date:  2000-10       Impact factor: 2.401

5.  Recognition by human gut gamma delta cells of stress inducible major histocompatibility molecules on enterocytes.

Authors:  E Griffith; E Ramsburg; A Hayday
Journal:  Gut       Date:  1998-08       Impact factor: 23.059

Review 6.  Pathogenesis of Adamantiades-Behçet's disease.

Authors:  Christos C Zouboulis; Tobias May
Journal:  Med Microbiol Immunol       Date:  2003-03-05       Impact factor: 3.402

Review 7.  Behçet's disease: from Hippocrates to the third millennium.

Authors:  D H Verity; G R Wallace; R W Vaughan; M R Stanford
Journal:  Br J Ophthalmol       Date:  2003-09       Impact factor: 4.638

8.  Behçet's syndrome.

Authors:  M R Stanford
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

9.  Molecular mechanisms in Behçet's disease.

Authors:  R Rajendram; N A Rao
Journal:  Br J Ophthalmol       Date:  2003-10       Impact factor: 4.638

10.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.